Roche Stock News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the Phase III INShore study of Gazyva® (obinutuzumab) in children and young adults (aged ≥ 2-25 years) with idiopathic nephrotic syndrome (INS). The study met its primary endpoint, with more people achi...

Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDT Company Participants Thomas Schinecker - Group Chief Executive Officer Alan Hippe - Chief Financial Officer Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Matthew Sause - Chief Executive Officer Bruno Eschli - Head of Investor Relations Conference Call Participants Richard Vosser - JPMorgan Chase & ...

The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.

Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Executive Committee effective 1 February 2026.

Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.

Angetrieben von einer starken Nachfrage nach Medikamenten ist der Schweizer Pharmakonzern Roche CH0012032048 in den ersten neun Monaten weiter gewachsen.

Der Pharmakonzern Roche CH0012032048 sieht sich auch über 2025 hinaus gut aufgestellt.

Angetrieben von einer starken Nachfrage nach Medikamenten ist der Schweizer Pharmakonzern Roche CH0012032048 in den ersten neun Monaten des Jahres weiter gewachsen.